ADvantage Therapeutics

A Dvantage Therapeutics

Biotechnology, Miami, Florida, 97759, United States, 11-50 Employees

advantagetherapeutics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +43********

Who is ADVANTAGE THERAPEUTICS

Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimers disease. The Co...

Read More

map
  • Miami, Florida, 97759, United States Headquarters: Miami, Florida, 97759, United States
  • 2021 Date Founded: 2021
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2731

checked-icon Does something look wrong? Fix it. | View contact records from ADVANTAGE THERAPEUTICS

ADvantage Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ADvantage Therapeutics

Answer: ADvantage Therapeutics's headquarters are located at Miami, Florida, 97759, United States

Answer: ADvantage Therapeutics's phone number is +43********

Answer: ADvantage Therapeutics's official website is https://advantagetherapeutics.com

Answer: ADvantage Therapeutics's revenue is Under $1 Million

Answer: ADvantage Therapeutics's SIC: 2731

Answer: ADvantage Therapeutics has 11-50 employees

Answer: ADvantage Therapeutics is in Biotechnology

Answer: ADvantage Therapeutics contact info: Phone number: +43******** Website: https://advantagetherapeutics.com

Answer: Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimers disease. The Companys lead compound AD04TM is an injectable therapy in the process of entering into a confirmatory Phase 2b clinical trials in Europe to evaluate safety and efficacy of the product in early Alzheimers Disease. The Company believes that AD04TM may act as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to the aggregation of the proteins present once pathology is present. The Company is also exploring additional approaches to mitigating neurodegenerative disease, which it believes will eventually have an overall impact on longevity.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access